Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

Authors

Ajai Chari, Mount Sinai School of Medicine
A. Keith Stewart, Mayo Clinic - Scottsdale
Stuart D. Russell, Duke University Medical Center
Philippe Moreau, University Hospital Hotel-Dieu
Joerg Herrmann, Mayo Clinic College of Medicine
Jose Banchs, The University of Texas MD Anderson Cancer Center
Roman Hajek, University of Ostrava
John Groarke, Brigham and Women's Hospital
Alexander R. Lyon, Imperial College London
George N. Batty, Amgen Inc.
Sunhee Ro, Amgen Inc.
Mei Huang, Amgen Inc.
Karim S. Iskander, Amgen Inc.
Daniel Lenihan, Washington University School of Medicine in St. Louis

Journal

Blood Advances

Publication Date

2018

Volume

2

Issue

13

Inclusive Pages

1633-1644

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2017015545

Rights and Permissions

Chari, A., Stewart, A. K., Russell, S. D., Moreau, P., Herrmann, J., Banchs, J., Hajek, R., Groarke, J., Lyon, A. R., Batty, G. N., Ro, S., Huang, M., Iskander, K. S., & Lenihan, D. (2018). Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Advances, 2(13), 1633-1644. https://doi.org/10.1182/bloodadvances.2017015545.

Recommended Citation

Chari, Ajai; Stewart, A. Keith; Russell, Stuart D.; Moreau, Philippe; Herrmann, Joerg; Banchs, Jose; Hajek, Roman; Groarke, John; Lyon, Alexander R.; Batty, George N.; Ro, Sunhee; Huang, Mei; Iskander, Karim S.; and Lenihan, Daniel, "Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials." Blood Advances. 2, 13. 1633-1644. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7246